![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
September 5, 2025
This clinical trial is testing a new treatment approach for patients with gastric carcinomatosis
September 19, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
August 28, 2025
This study is now assessing blood-based and imaging biomarkers to identify patients at elevated risk of pancreatic cysts becoming cancerous
June 11, 2025
Dr. Grivas is honored as an international key opinion thought leader who has made outstanding contributions to genitourinary cancer research, clinical practice, leadership, teaching and mentorship, and community outreach
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
February 19, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
July 3, 2024
Summaries of recently published ECOG-ACRIN research results